Looking for treatment? Call or text (888) 835-9995 to start care today — or return to the homepage.
Standard panels and fentanyl
Fentanyl is not detected on most standard drug screens.
Fentanyl is a synthetic opioid — it does not cross-react with standard opiate immunoassay tests, which are calibrated to detect morphine and its metabolites. A standard 5-panel or 10-panel drug test will not detect fentanyl.
Fentanyl-specific immunoassay panels are widely available and are increasingly used in clinical settings, emergency medicine, and some other testing contexts. These require deliberate addition to a testing panel — they are not included by default.
Detection windows
How long fentanyl is detectable.
Fentanyl is highly lipophilic and metabolized rapidly by the liver to norfentanyl. Detection windows are relatively short compared to many other opioids.
Urine
Fentanyl and its primary metabolite norfentanyl are often detectable in urine for about 24–72 hours after last use. In some patients with heavy or chronic use, detection may persist longer, including beyond several days. Norfentanyl often remains detectable longer than fentanyl itself.
Blood
Fentanyl has a rapid distribution phase and is often detectable in blood for a relatively short period, commonly on the order of hours after administration. Blood testing is primarily used in clinical and forensic contexts rather than workplace screening.
Hair
Hair follicle testing may detect fentanyl for up to about 90 days, consistent with standard hair testing windows. However, fentanyl's low-dose administration and high potency can make hair detection less reliable than for other opioids.
Fentanyl in the current overdose context
Fentanyl contamination in the illicit drug supply.
Illicitly manufactured fentanyl has become the dominant driver of opioid overdose deaths in the United States. It is present in many illicit drug supplies — including substances not typically associated with opioids — and is active at microgram doses, making accidental exposure a significant risk.
This context affects clinical practice: patients who have been using illicit opioids may now present with fentanyl exposure regardless of their reported drug of choice. Buprenorphine initiation in the fentanyl era has led to evolving clinical approaches, including higher-dose and modified induction strategies in some settings.
See our fentanyl treatment page for more on how fentanyl affects buprenorphine initiation.
Sources
Where this information comes from.
Narrative review of fentanyl pharmacokinetics including urine detection windows, norfentanyl persistence, and clinical significance related to illicitly manufactured fentanyl.
Huhn AS et al. — Protracted Renal Clearance of Fentanyl in OUD (Drug Alcohol Depend, 2020)
Documents extended fentanyl detection windows in patients with opioid use disorder, including cases exceeding one week.
Current data on fentanyl's role in overdose deaths in the United States.
ASAM: Buprenorphine in the Fentanyl Era (2023)
Updated clinical considerations for buprenorphine initiation in patients with fentanyl use.